News

Cell2B launches BoostPharma

03 June 2015
Logo_BoostPharma_no background

BoostPharma Advanced Therapies is a one-stop shop for cell therapies, providing the pharmaceutical industry with a full range of services for advanced therapy products across the product development cycle. BoostPharma is a Cell2B spin off operating the state of the art facility in construction at Biocant Park. More information here.

Cell2B is granted Orphan Designation for Prevention of GvHD

09 January 2015
Untitled-1

Cell2B is granted Orphan Medical Product Designation EU/3/14/1388 for Prevention of Graft-versus-Host Disease (GvHD) by the European Commission upon positive opinion by the Committee for Orphan Medicinal Products. This new designation comes on top of Orphan Designation for GvHD treatment granted in 2013 (EU/3/13/1129). Cell2B is strongly committed to deliver new therapies that tackle this unmet clinical need. GvHD is the lead indication of a larger set of immune indications Cell2B is addressing. More information here.

Cell2B appoints international advisory board

29 April 2014

Cell2B is honored to make public our long term commitment with our Advisory Board. Charles Cooney (PhD), Duke Collier (JD), and Frederic Chereau (MBA) have been very active since Cell2B’s incorporation. They bring outstanding experience in industry from start-up to corporate level and from rare diseases to cell therapies.

 

cooney300x300Charles L. Cooney is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering at MIT. He serves as a consultant to a number of biotech and pharma companies and sits on the Boards of Directors of Polypore International, Inc., LS9, Inc., Mitra (India), GreenLight Bioscience, Essentient, Inc. and Biocon, Ltd (India) and was previously on the Boards of Genzyme, Cuno, Inc., Pall Corp. and Astra.

 

 

CollierEarl M. (Duke) Collier, Jr. is Executive Chairman of Arsenal Medical and serves as CEO of 480 Biomedical. For many years, Mr. Collier was executive vice president at Genzyme Corporation. He has also served as president of Vitas Healthcare and a partner at the law firm of Hogan and Hartson. Mr. Collier sits on the boards of 480 Biomedical, Arsenal Medical, Capricor, Transmedics and Newton-Wellesley Hospital.

 

 

ChereauFrederic Chereau serves as president and chief operating officer of aTyr Pharma. Previously, Mr. Chereau was senior vice president of Global Angioedema Franchise Lead at Shire, chief executive officer of Pervasis Therapeutics (acquired by Shire in 2012),  vice president and general manager of the Cardiovascular Business Unit at Genzyme from 1999 to 2008, and he started his career at Hemotech.

 

 

More information here.

Gilbert Wagener Appointed Interim CMO at Cell2B

28 April 2014
Gilbert Wagener

Cell2B appointed Gilbert Wagener (MD, PhD, MBA) as interim Chief Medical Officer. This appointment is crucial for the transition to clinical development of Cell2B’s leading product ImmuneSafe. Dr. Wagener will be responsible for clinical development and clinical trial operations. Dr. Wagener has a long career in the industry with a focus on clinical development for oncology, cardiovascular, and CNS indications, including stem cell-based therapies. Dr Wagener is a Partner at Transcrip Partners in Reading, UK. Before joining Cell2B, he was VP of Genzyme Europe B.V. in different areas for 16 years and he was director for global cardiovascular clinical strategy at Bayer Healhcare AG.

Cell2B as one of the “10 new companies to watch” by Alexey Bersenev

28 April 2014

Cell2B is one of the 10 new companies to watch (here), a selection by Alexey Berseney published in Stem Cell Assays. According to Dr. Berseney,Cell2B represents the second generation of MSC companies. Like monoclonal antibodies, we expect that the second generation exceeds the exceptions for cell therapies.

Cell2B is proud to be recognized by Dr. Berseney one of the leading technologists in cell therapies and stem cell technology. The development of new generation products will undoubtly overcome the main limitation the field has been facing and Cell2B is honored to be an active player in leading this effort.

 

Cell2B @ ISCT from April 23-26 in Paris

08 April 2014

Cell2B will actively participate at the ISCT meeting from April 23-26 in Paris. If you want to reach out to us, do not hesitate in contacting at cell2b@cell2b.com.

ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients’ lives. More information in the ISCT meeting here.

Cell2B’s Founding CEO, Daniela Couto, Interview at COTEC Newsletter

08 April 2014

Check Cell2B’s founding CEO Interview at COTEC’s monthly Newsletter. You can see the full interview in Portuguese here.

COTEC Portugal – Associação Empresarial para a Inovação – was created in April 2003, following an initiative of the President of Portugal. With the mission of «promoting the competitiveness of companies established in Portugal, through the development and the diffusion of a culture and a practice of innovation as well as of knowledge, especially that generated in our country», COTEC Portugal is a not for profit business association that counts on the support of its 290 associated companies.

Cell2B @ EBMT 2014

08 April 2014

Cell2B has participated in the EBMT 2014 from 30 March – 2 April 2014 • Milan, Italy

This was the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation.

See more information here.